-
Vorsetuzumab: Advancing Cancer Research with CD70 Targeting(Post)
What You Need to Know About VorsetuzumabWhat is Vorsetuzumab?Vorsetuzumab is a monoclonal antibody targeting CD70, a protein found in various cancers. It shows promise for advancing canc
LILT: A Novel Immune Checkpoint for Cancer Therapy(Post)Recent advances in immunotherapy have highlighted the importance of targeting immune checkpoints to enhance the immune system’s ability to combat cancer. A new potential target in this gr
PharmaGenie ELISA Kits(Page)PharmaGenie ELISA Kits | ISO-Validated BioPharma ELISA | Assay Genie
CD28: Amplifying T Cell Responses for Better Tumor Clearance(Post)The CD28 molecule plays a crucial role in amplifying T cell activation, which is critical for mounting effective immune responses against tumors. By engaging with co-stimulatory molecules
Gemtuzumab: Advancing CD33-Targeted Therapies in AML Research(Post)Key Facts About GemtuzumabWhat is Gemtuzumab?Gemtuzumab is an antibody-drug conjugate (ADC) targeting CD33, a protein expressed on the surface of myeloid cells. It is widely recognized f
Ifabotuzumab: Exploring the Role of Anti-EphA3 in Cancer Research(Post)What You Need to Know About IfabotuzumabWhat is Ifabotuzumab?Ifabotuzumab is a monoclonal antibody targeting EphA3, a receptor tyrosine kinase overexpressed in certain cancers. It plays
Coronavirus Assays(Page)Coronavirus Assays | SARS-CoV-2 ELISA, Multiplex, Rapid & PCR | Assay Genie
CD47: Overcoming Tumor Evasion Through Macrophage Activation(Post)One of the greatest challenges in cancer therapy is how tumors evade immune detection. Among the mechanisms cancer cells exploit, the CD47 pathway has emerged as a major player in helping
Milatuzumab: Unveiling Its Role in Cancer Immunotherapy and Research(Post)What You Need to Know About MilatuzumabWhat is Milatuzumab?Milatuzumab is a humanized monoclonal antibody targeting CD74, a molecule involved in antigen presentation and cell signaling.W
Indatuximab: Advancing CD138-Targeted Therapy in Cancer Research(Post)What You Need to Know About IndatuximabWhat is Indatuximab?Indatuximab ravtansine is an experimental monoclonal antibody-drug conjugate (ADC) that targets CD138, a protein highly express
The NLRP3 inflammasome & pyroptosis(Page) Obinutuzumab: Advancing Targeted Therapy in Hematologic Cancers(Post)Quick Facts About ObinutuzumabWhat is Obinutuzumab?Obinutuzumab is a monoclonal antibody targeting CD20, primarily used in treating B-cell malignancies such as chronic lymphocytic leukem
Interactive Pathway Diagrams(Page) Daratumumab: Advancing Research in Multiple Myeloma and Beyond(Post)Key Facts About DaratumumabWhat is Daratumumab?Daratumumab is a monoclonal antibody that targets CD38, a protein highly expressed on the surface of multiple myeloma cells.How does Daratu
cGAS-STING cytosolic DNA sensing(Page) IgA Test – Normal Ranges, Results & What They Mean(Post)Clinical · Immunology Guide IgA Test: Normal Ranges, Results & What They Mean [2026] What the immunoglobulin A blood test measures, how result
Pinatuzumab: Advancing Cancer Research and Therapeutics(Post)Quick Facts About PinatuzumabWhat is Pinatuzumab?Pinatuzumab is an antibody-drug conjugate (ADC) designed to target CD22, a protein highly expressed on B-cell malignancies, including non
Praluzatamab: Unveiling the Promise of CD47-Targeted Therapy in Cancer Research(Post)Quick Facts About PraluzatamabWhat is Praluzatamab?Praluzatamab is an experimental monoclonal antibody that targets CD47, a “don’t eat me” signal used by cancer cells to evade immune des
Brochures and Flyers(Page)Free Brochures & Flyers — Product Guides | Assay Genie
TGF-β/SMAD signalling(Page) Brentuximab: Unveiling the Role of Anti-CD30 in Cancer Research(Post)Key Facts About BrentuximabWhat is Brentuximab?Brentuximab is a monoclonal antibody targeting CD30, commonly used in the treatment of Hodgkin lymphoma and systemic anaplastic large cell
Belantamab: A Game-Changer in Multiple Myeloma Therapy(Post)Quick Facts About BelantamabWhat is Belantamab?Belantamab Mafodotin is a cutting-edge antibody-drug conjugate (ADC) designed for the treatment of relapsed or refractory multiple myeloma.
Naratuximab: Redefining Cancer Therapy with Precision Medicine(Post)Quick Facts About NaratuximabWhat is Naratuximab?Naratuximab is an anti-CD37 monoclonal antibody-drug conjugate (ADC) designed to target B-cell malignancies, particularly non-Hodgkin lym
MHC Class I vs Class II: Key Differences & Functions [Guide](Post)Immunology Guide MHC Class I vs Class II: Key Differences & Functions [Guide] Major Histocompatibility Complex molecules present antigens to T
Tgf beta smad pathway · HT(Page) Labetuzumab: Revolutionizing Cancer Research with Targeted Therapies(Post)Quick Facts About LabetuzumabWhat is Labetuzumab?Labetuzumab is a monoclonal antibody targeting CEACAM5, a protein overexpressed in various cancers, primarily colorectal carcinoma.How do
Custom ELISA Kits(Page)Custom ELISA Kit Development Service | Assay Genie
Macrophage phagocytosis cd47 sirpa pathway (Page) Varlilumab: Unlocking CD27’s Potential in Cancer Research(Post)What You Need to Know About VarlilumabWhat is Varlilumab?Varlilumab is a monoclonal antibody targeting CD27, a receptor on T-cells that plays a critical role in immune modulation.What is
Infectious Disease ELISA(Page)Pathogen Antibodies, Proteins & ELISA Kits | Infectious Disease | Assay Genie
Pi3k akt mtor pathway · HTML(Page) Western Blot Protocol & Troubleshooting Guide(Page)Western Blot Protocol & Troubleshooting Guide | 14 Steps + 101 Tips | Assay Genie
ICOS: Stimulating the Immune System for Superior Cancer Therapy(Post)Immunotherapy has transformed the landscape of cancer treatment by leveraging the body’s immune system to target and destroy cancer cells. A key player in this process is Inducible T-cell
Magrolimab: Unveiling the Role of Anti-CD47 in Cancer Research and Beyond(Post)What You Need to Know About MagrolimabWhat is Magrolimab?Magrolimab is an anti-CD47 monoclonal antibody that targets the "don't eat me" signal on cancer cells, promoting their destructio
Enavatuzumab: Revolutionizing Cancer Research Through Novel Therapeutics(Post)Quick Facts About EnavatuzumabWhat is Enavatuzumab?Enavatuzumab is a monoclonal antibody targeting the TWEAK receptor (Fn14), pivotal in tumor growth and immune regulation.What is the me
Enfortumab Vedotin: Unveiling Its Role in Cancer Treatment and the Rise of Biosimilars(Post)Quick Facts About EnfortumabWhat is Enfortumab Vedotin?Enfortumab vedotin is an innovative cancer therapy, primarily used in treating urothelial carcinoma (bladder cancer) that has not r
Talacotuzumab: Exploring CD123-Targeting Therapies in AML and MDS Research(Post)Key Facts About TalacotuzumabWhat is Talacotuzumab?Talacotuzumab is a monoclonal antibody designed to target CD123, a protein commonly found on the surface of certain blood cancer cells.
Alemtuzumab: Mechanism, Applications, and Biosimilar Advancements(Post)Quick Facts About AlemtuzumabWhat is Alemtuzumab?Alemtuzumab is a monoclonal antibody targeting CD52, primarily used in the treatment of multiple sclerosis (MS) and certain cancers like
B7-H4: A New Frontier in Immune Checkpoint Inhibition(Post)The recent advances in cancer immunotherapy have brought new opportunities to harness the body’s immune system against tumors. Among these advancements is the targeting of immune checkpoi
Alsevalimab: Targeting CD47 for Cancer Research and Treatment(Post)Quick Facts About AlsevalimabWhat is Alsevalimab?Alsevalimab is a monoclonal antibody targeting CD47, a protein involved in immune evasion by cancer cells. By blocking CD47, Alsevalimab
Passaging Hybridoma Cells: A Detailed Guide(Post)Cell Culture · ProtocolsPassaging Hybridoma Cells: A Detailed GuideHybridomas are productive but temperamental. They grow in suspension, are sensitive to shear and to overgrowth, and — the problem tha
Apoptosis pathway · HTML(Page) Nfkb signalling pathway · HTML(Page) Girentuximab: Exploring Its Mechanism, Clinical Potential, and Research Advancements(Post)Quick Facts About GirentuximabWhat is Girentuximab?Girentuximab is a monoclonal antibody targeting carbonic anhydrase IX (CAIX), predominantly expressed in renal cell carcinoma (RCC) cel
ELISpot Assay Kits(Page) Assay Genie Mission(Page)Assay Genie Mission | Making Scientists Smile
Siltuximab: Exploring IL-6 Inhibition in Castleman’s Disease and Research(Post)Quick Facts About SiltuximabWhat is Siltuximab?Siltuximab is a monoclonal antibody targeting interleukin-6 (IL-6), a cytokine involved in inflammation and immune regulation.What is the m
Multiplex Assays(Page)GeniePlex Multiplex Assays | Bead-Based Multiplex Immunoassays | Assay Genie
Mogamulizumab: Understanding Its Mechanism, Clinical Applications, and the Role of Biosimilars in Research(Post)Quick Info Section: Key Facts About MogamulizumabWhat is Mogamulizumab?Mogamulizumab is an anti-CCR4 monoclonal antibody used primarily for treating certain cancers, including cutaneous
CD27 Activation: Strengthening the Immune Army Against Cancer(Post)Harnessing the immune system to fight cancer has become a pivotal strategy in modern oncology. A key component in this fight is CD27, a receptor that plays a crucial role in T-cell activa
Etigilimab: Unveiling the Role of Anti-TIGIT in Cancer Research(Post)Key Facts About EtigilimabWhat is Etigilimab?Etigilimab is an anti-TIGIT monoclonal antibody being studied for its potential role in cancer immunotherapy.What role does Etigilimab play i
Rituximab: Mechanism, Applications, and Research Potential(Post)Quick Facts About RituximabWhat is Rituximab?Rituximab is a monoclonal antibody targeting CD20, a protein found on the surface of B cells. It plays a crucial role in treating autoimmune
Patritumab Deruxtecan: Mechanism, Clinical Applications, and Biosimilar Advances(Post)Quick Facts About Patritumab DeruxtecanWhat is Patritumab Deruxtecan?Patritumab Deruxtecan (HER3-DXd) is an investigational antibody-drug conjugate (ADC) targeting HER3, a receptor impli
Lorvotuzumab: Targeting CD56 in Cancer Research and Therapeutic Development(Post)Quick Facts About LorvotuzumabWhat is Lorvotuzumab?Lorvotuzumab is an antibody-drug conjugate (ADC) designed to target CD56, a surface antigen commonly overexpressed in neuroendocrine tu
Cevostamab: Unveiling the Role of Anti-CD47 in Cancer Research(Post)Quick Info Section: Key Facts About CevostamabWhat is Cevostamab?Cevostamab is an investigational monoclonal antibody targeting CD47, a cell surface protein that helps cancer cells evade
Tisotumab Vedotin: A Breakthrough in Targeted Cancer Therapy(Post)Quick Facts About Tisotumab VedotinWhat is Tisotumab Vedotin?Tisotumab Vedotin (Tivdak™) is an antibody-drug conjugate (ADC) designed to target tissue factor (TF) and is FDA-approved for
Aducanumab: Mechanism, Clinical Applications, and the Role of Biosimilars in Research(Post)Quick Facts About AducanumabWhat is Aducanumab?Aducanumab is a monoclonal antibody designed to target and reduce amyloid-beta plaques in the brain, a hallmark of Alzheimer’s disease.What
Denosumab: A Comprehensive Overview of Mechanism, Applications, and Research Advances(Post)Biologics · Bone MetabolismDenosumab: RANKL Inhibition, Clinical Applications and BiosimilarsDenosumab is a fully human monoclonal antibody against RANKL, the cytokine that drives osteoclast formation
Pembrolizumab: Unveiling Its Mechanism and Research Applications with Biosimilars(Post)Key Facts: PembrolizumabIs Pembrolizumab Safe?Pembrolizumab is widely recognized as safe for most patients, with side effects ranging from mild to severe. Commonly reported side effects
Leukocyte adhesion cascade(Page) Sacituzumab: Exploring its Role in Cancer Research and the Rise of Biosimilars(Post)Key Facts About SacituzumabWhat is Sacituzumab?Sacituzumab is an antibody-drug conjugate (ADC) that targets the tumor-associated antigen Trop-2, used to treat various cancers, including
KIR Blockade: Empowering NK Cells for Superior Tumor Clearance(Post)Introduction to KIR Blockade in Cancer ImmunotherapyNatural killer (NK) cells are crucial components of the innate immune system, responsible for recognizing and destroying virally infec
Iscalimab: Advancing Research in Autoimmune Diseases and Transplantation(Post)What You Need to Know About IscalimabWhat is Iscalimab?Iscalimab (CFZ533) is a monoclonal antibody targeting CD40, a key protein involved in immune system regulation.What is the mechanis
Rosopatamab: Unveiling the Potential of Anti-CD47 Therapy in Cancer Research(Post)Quick Facts About RosopatamabWhat is Rosopatamab?Rosopatamab is a monoclonal antibody targeting CD47, a critical immune checkpoint that helps cancer cells evade immune detection. By bloc
Bcell germinal centre pathway(Page) Amatuximab: Exploring Mesothelin-Targeted Therapy for Cancer Research(Post)What You Need to Know About AmatuximabIs Amatuximab safe?Amatuximab has shown a manageable safety profile in clinical trials, with most side effects being mild to moderate. Severe advers
Zilovertamab: Unlocking the Potential of ROR1-Targeted Therapy(Post)Quick Facts About ZilovertamabWhat is Zilovertamab?Zilovertamab is a monoclonal antibody targeting ROR1, a receptor tyrosine kinase overexpressed in hematologic cancers and solid tumors.
Talquetamab: Exploring its Role in Cancer Therapy and Ongoing Research(Post)Quick Info Section: Key Facts About TalquetamabWhat is Talquetamab?Talquetamab is a novel monoclonal antibody being developed for the treatment of multiple myeloma and other cancers. It
NK Cell Cytotoxicity Pathway: Receptors, Signalling and Assays(Post)A natural killer cell decides by subtraction. It carries no rearranged antigen receptor and no memory of what it has seen. It presses a panel of germline-encoded receptors against a target and integr
Nfkb signalling pathway · HTM(Page) Tigatuzumab: Advancing Cancer Research with Targeted Therapies(Post)Quick Facts About TigatuzumabWhat is Tigatuzumab?Tigatuzumab is a monoclonal antibody that targets the death receptor 5 (DR5) pathway, inducing apoptosis in cancer cells.What is the mech